Cancer
Oesophageal squamous cell carcinoma in Shantou
汕头 食管鳞状细胞癌
2 hospitals in Shantou
Order: papers led on oesophageal squamous cell carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for oesophageal squamous cell carcinoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shantou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 66 papers led
- 4 papers ledNo open trial led
Oesophageal squamous cell carcinoma in every city Shantou on the disease page, with the national map
open trials on oesophageal squamous cell carcinoma with a hospital in Shantou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with a listed hospital in Shantou as lead sponsor or study site. 2 of them are led by a hospital in Shantou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07700667
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingIntestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07339488
Age 18 years to 75 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
- RecruitingBenmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06637163
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin
- RecruitingAdjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT05984342
Age 18 years to 70 years (registered criteria)
Led by Shantou University Medical College hospitalsShantou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Shantou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Shantou Central Hospital汕头市中心医院 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shantou Chaonan Minsheng Hospital汕头潮南民生医院 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shantou Hospital汕头市中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shantou University Medical College hospitals汕头大学医学院附属医院 | 8 | 662 open | 25 | 26 | 0 | none | none | 9 | none | none | none | none | none | none | none | 3 | 0 | none | none | none | none | none | none | none | none | 0 | none | none | 1 | 2 | 1 | 1 | none | none | none | none | none | none | 2 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Shantou.
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 662 open
- Hepatocellular carcinoma 25
- Stomach cancer 26
- Hepatoblastoma 0
- Osteosarcoma 9
- Beta thalassaemia 3
- Haemophilia A 0
- Biliary atresia 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 2
- Osteogenesis imperfecta 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for oesophageal squamous cell carcinoma.
Counts are listed hospitals only, not every hospital in each city.
- 35 kmJieyang揭阳None listed for oesophageal squamous cell carcinoma
- 117 kmMeizhou梅州None listed for oesophageal squamous cell carcinoma
- 156 kmZhangzhou漳州None listed for oesophageal squamous cell carcinoma
- 188 kmXiamen厦门3 hospitals for oesophageal squamous cell carcinoma
- 237 kmHuizhou惠州None listed for oesophageal squamous cell carcinoma
- 255 kmQuanzhou泉州1 hospital for oesophageal squamous cell carcinoma
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shantou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.